How GW7647 can Save You Time, Stress, and Money.
All enrolled individuals who gained at the very least one dose of zosuquidar or placebo through induction were being monitored for the event of adverse gatherings (439 people, 219 on zosuquidar and 210 on placebo). The most common adverse events had been relevant to the duration of prolonged and sizeable myelosuppression as is anticipated with indu